Is there a role for bortezomib combinations in the management of patients with follicular lymphoma?

Journal of Clinical Oncology

Volumn 29, Issue 25, 2011, Pages 3349-3350

  Salles, Gilles ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; I KAPPA B; PREDNISONE; RITUXIMAB; VINCRISTINE;

CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDITORIAL; FOLLICULAR LYMPHOMA; HEMATOLOGIC DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY;

EID: 80052696399     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.5586     Document Type: Editorial

References (19)

1. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 27:1202-1208, 2009
2. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
3. Pulte D, Gondos A, Brenner H: Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 168:469-476, 2008 (Pubitemid 351559319)
4. Voorhees PM, Dees EC, O'Neil B, et al: The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325, 2003 (Pubitemid 38031815)
5. Strauss SJ, Higginbottom K, Jüliger S, et al: The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 67:2783-2790, 2007 (Pubitemid 46548967)
6. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005 (Pubitemid 46224166)
7. Strauss SJ, Maharaj L, Hoare S, et al: Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24:2105-2112, 2006 (Pubitemid 46622122)
8. Di Bella N, Taetle R, Kolibaba K, et al: Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 115:475-480, 2010
9. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005 (Pubitemid 46237441)
10. Gerecitano J, Portlock C, Moskowitz C, et al: Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 146:652-655, 2009
11. Ribrag V, Tilly H, Casasnovas O, et al: Final results of a randomized phase 2 multicenter study of two bortezomib schedules in patients with recurrent or refractory follicular lymphoma: Groupe d'Etude des Lymphomes de l'Adulte (GELA) Study FL-05. Blood 116, 2010 (abstr 768)
12. Orlowski RZ: The ubiquitin proteasome pathway from bench to bedside. Hematology Am Soc Hematol Educ Program 220-225, 2005
13. Fowler N, Kahl BS, Lee P, et al: Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study. J Clin Oncol 29:3389-3395, 2011
14. Sehn LH, MacDonald D, Rubin S, et al: Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 29:3396-3401, 2011
15. Robinson KS, Williams ME, Van der Jagt RH, et al: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26:4473-4479, 2008
16. Friedberg JW, Vose JM, Kelly JL, et al: The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117:2807-2812, 2011
17. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
18. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
19. Coiffier B, Osmanov E, Hong X, et al: A phase 3 trial comparing bortezomib plus rituximab with rituximab alone in patients with relapsed, rituximab-naive or -sensitive follicular lymphoma. Blood 116, 2010 (abstr 857)